Efficacy of a multiple-indication antiviral herbal drug (Saliravira®) for COVID-19 outpatients: A pre-clinical and randomized clinical trial study

Efficacy of a multiple-indication antiviral herbal drug (Saliravira®) for COVID-19 outpatients: A pre-clinical and randomized clinical trial study

The scientific researches on COVID-19 pandemic topics are headed to an explosion of scientific literature. Despite these global efforts, the efficient treatment of patients is an in-progress challenge. Based on a meta-study of published shreds of evidence about compounds and their botanic sources in...

Full description

Saved in:
Bibliographic Details
Published in:Biomedicine & pharmacotherapy Vol. 149; p. 112729
Main Authors: Khorshiddoust, Reza Ramazani, Khorshiddoust, Saleh Ramazani, Hosseinabadi, Tahereh, Mottaghitalab, Faezeh, Mokhtari, Farzad, Azadinia, Fatemeh, Mozdarani, Hossein, Shabani, Mohammad, Emadi-Kouchak, Hamid, Taheri, Bahram, Khani-Juyabad, Fatemeh, Kashani, Mina Amjadi, Sadoughi, Arezoo, Zamanizadeh, Sorour, Maddah, Hadyeh, Aminzadeh, Maedeh, Khanaki, Maryam, Saremi, Sabereh, Rad, Anahita Pashaee, Fatehi, Ali, Rad, Melika Ghaznavi, Haftbaradaran, Masoud, Khosroshahi, Mehran, Sadeghi, Mahtab, Aminnayeri, Majid, Jafari, Sirous, Ghiasvand, Fereshteh, Seifi, Arash, Ghaderkhani, Sara, Manshadi, Seyed Ali Dehghan, Salehi, Mohammadreza, Abbasian, Ladan, Hasannezhad, Malihe, Meidani, Mohsen, Hajiabdolbaghi, Mahboubeh, Ahmadinejad, Zahra, Parash, Masoud, Sedighi, Zahra, Mohammadian, Abdorreza
Format: Journal Article
Language:English
Published: France Elsevier Masson SAS 01-05-2022
Published by Elsevier Masson SAS
Elsevier
Subjects:
Antiviral agent
Antiviral Agents - therapeutic use
COVID-19
COVID-19 Drug Treatment
Herbal medicine
Humans
Immune-enhancing
Outpatient
Outpatients
Pandemics
Saliravira
SARS-CoV-2
Treatment Outcome
COVID-19
Herbal medicine
Immune-enhancing
Antiviral agent
Outpatient
Saliravira
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The scientific researches on COVID-19 pandemic topics are headed to an explosion of scientific literature. Despite these global efforts, the efficient treatment of patients is an in-progress challenge. Based on a meta-study of published shreds of evidence about compounds and their botanic sources in the last six decades, a novel multiple-indication herbal compound (Saliravira®) has been developed. Based on the antiviral, anti-inflammatory, and immune-enhancing properties of its ingredients, we hypothesized that Saliravira® has the potential to act as an antiviral agent, accelerate treatment, and reduce undesirable effects of COVID-19. In this randomized, controlled, open-label clinical trial, COVID-19 outpatients were included by RT-PCR test or diagnosis of physicians according to the symptoms. Participants were randomly divided into intervention and control groups to receive Saliravira® package plus routine treatments of COVID-19 or routine treatments of COVID-19 alone, respectively. Saliravira® package includes tablets, nasal-sinuses spray, oral-pharynx spray, and inhaler drops. The treatment was for 10 days and followed up till 23 days after admission. On the 8th day, the “mean reduction rates” of viral load of the patients in the intervention group was 50% lower compared to the control group with a p-value < 0.05. The improvement of 10 out of 14 COVID-19 symptoms in the intervention group was significantly accelerated. The mean treatment duration of patients in the intervention group was 4.9 days less than the control group. In addition, no patients in the intervention group were hospitalized compared to 28% of the control group needed to be hospitalized. [Display omitted] •Saliravira® is a natural medicine; composed of Echinacea purpurea, Glycyrrhiza glabra, Rheum palmatum, Hyssopus officinalis, Rosmarinus officinalis, and Panax ginseng.•Saliravira® has the potential to act as an antiviral, anti-inflammatory, and immune-enhancing agent for treatment of COVID-19.•Toxicity studies on mice did not show significant difference between control and intervention groups.•Clinical trial results indicated, viral loads of the patients in the intervention group on the 8th day after the start of treatment was significantly lower in comparison to the control group.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:0753-3322
1950-6007
DOI:10.1016/j.biopha.2022.112729